Biogen Inc., known by its stock symbol BIIB, is a leading multinational biotechnology company based in the United States. The company was originally founded in 1978 in Geneva, Switzerland, and is now headquartered in Cambridge, Massachusetts. Biogen has gained recognition as one of the world’s oldest independent biotechnology companies, with a reputation for pioneering development of therapies for neurodegenerative, hematologic, and autoimmune diseases.
Biogen's primary focus is on developing medicines for diseases with few or no treatment options. Over the years, it has secured the global marketing rights for a variety of significant products which address medical conditions like multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease.
One of Biogen's prominent products is TECFIDERA, a medicine for relapsing forms of MS. The company also made significant strides in SMA treatment with the development of SPINRAZA, a great achievement in the infant mortality combat.
Biogen's forward-thinking approach on R&D investment has led to a strong product pipeline. In March 2021, Biogen gained attention when its Alzheimer’s treatment, Aduhelm, became the first new Alzheimer’s medicine approved by the U.S. Food and Drug Administration (FDA) in nearly 20 years. However, the drug’s approval has been met with some controversy due to concerns about clinical trial data and its pricing.
In recent years, Biogen has also made strides in corporate responsibility, committing to carbon neutrality, and tackling diversity and inclusion. It has received recognition for its efforts in these areas, including featuring in the Dow Jones Sustainability World Index.
Biogen is publicly traded on the NASDAQ and forms part of the S&P 500 and NASDAQ-100. The company has shown significant growth and financial strength over the years with increasing revenue from a growing portfolio of drugs.
Under its current CEO Michel Vounatsos, Biogen continues to intensify its research and development activities, seeking to create new groundbreaking therapies, and deliver on its mission to improve the lives of those affected by serious diseases worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Biogen (BIIB) has recently reported strong earnings and new product news, including the LEQEMBI Pen approval in Japan, leading to a 5.6% share price increase over the past week and 28.0% year-to-date. The company is currently estimated to be 4% undervalued with a fair value of $236.22, driven by a robust late-stage pipeline. However, its high P/E ratio of 40.3x, compared to the sector average of 17.1x, presents conflicting signals for investors.
City Therapeutics, an RNAi biotech co-founded by Alnylam founder Maraganore, has filed for an initial public offering (IPO) on Nasdaq under the ticker CTY. The company, which has raised approximately $238.8 million since its launch in October 2024, currently employs 81 people and has established partnerships with Bausch + Lomb and Biogen. The IPO aims to build on the success of Alnylam Pharmaceuticals Inc.
Prime Medicine (NASDAQ: PRME) has received FDA clearance for its Investigational New Drug (IND) application for PM647, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The company plans to initiate a global Phase 1/2 clinical trial to assess the safety and efficacy of PM647, which aims to correct the E342K (Pi*Z) mutation in the SERPINA1 gene. PM647 is designed to restore functional M-AAT protein levels to address both liver and lung complications of AATD.
ACADIA Pharmaceuticals reported positive Phase 2 RADIANT data for remlifanserin in Alzheimer’s disease psychosis, showing clinical improvements and a favorable safety profile. The company plans to advance ongoing Phase 3 studies and present detailed data at an upcoming conference. This progress supports ACADIA's strategy to diversify its revenue streams beyond its current key products, despite some concerns about the drug's modest effect size.
QRG Capital Management Inc. significantly increased its stake in Deckers Outdoor Corporation ($DECK) during the second quarter, purchasing 51,081 additional shares to own a total of 58,724 shares valued at $5.83 million. Institutional ownership of Deckers Outdoor remains high at 97.79%, with other major financial institutions also establishing or expanding their positions. Despite the stock trading near $78.61, below its average target price of $114.42, Deckers Outdoor recently reported strong quarterly earnings, beating EPS estimates and showing a 5.7% year-over-year revenue increase.
Envestnet Asset Management Inc. significantly increased its stake in Merck & Co., Inc. during the second quarter, now holding nearly 4 million shares valued at $513.6 million. Institutional investors collectively own 76.07% of Merck, reflecting strong confidence. Analysts generally maintain a "Moderate Buy" rating with an average price target of $154.24, following Merck exceeding its recent quarterly earnings and revenue estimates.
Immunovant (NASDAQ: IMVT) is halting its cutaneous lupus development program after its Phase 2b trial for IMVT-1402, or imeroprubart, failed to meet its primary endpoint at Week 12. The study did not show a statistically significant difference in the CLASI-A score, though numerical trends favored treatment. Despite this setback, Immunovant will continue development for five other autoimmune indications, including Graves' disease and myasthenia gravis, with topline results expected in 2027.